SE9703691D0 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
SE9703691D0
SE9703691D0 SE9703691A SE9703691A SE9703691D0 SE 9703691 D0 SE9703691 D0 SE 9703691D0 SE 9703691 A SE9703691 A SE 9703691A SE 9703691 A SE9703691 A SE 9703691A SE 9703691 D0 SE9703691 D0 SE 9703691D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical compositions
pharmaceutical formulations
medium chain
bisphosphonate
osteoporosis
Prior art date
Application number
SE9703691A
Other languages
English (en)
Swedish (sv)
Inventor
Anna-Lena Ungell
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9703691A priority Critical patent/SE9703691D0/xx
Publication of SE9703691D0 publication Critical patent/SE9703691D0/xx
Priority to ZA988886A priority patent/ZA988886B/xx
Priority to EP03001707A priority patent/EP1310259A3/en
Priority to DK98948029T priority patent/DK1021194T3/da
Priority to AU94691/98A priority patent/AU9469198A/en
Priority to ES98948029T priority patent/ES2200378T3/es
Priority to DE69814656T priority patent/DE69814656T2/de
Priority to PT98948029T priority patent/PT1021194E/pt
Priority to ARP980104956A priority patent/AR015946A1/es
Priority to JP2000515605A priority patent/JP2001519398A/ja
Priority to US09/171,950 priority patent/US6372728B1/en
Priority to PCT/SE1998/001790 priority patent/WO1999018972A1/en
Priority to AT98948029T priority patent/ATE240107T1/de
Priority to SI9830488T priority patent/SI1021194T1/xx
Priority to EP98948029A priority patent/EP1021194B1/en
Priority to SA98190775A priority patent/SA98190775A/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE9703691A 1997-10-10 1997-10-10 Pharmaceutical compositions SE9703691D0 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE9703691A SE9703691D0 (sv) 1997-10-10 1997-10-10 Pharmaceutical compositions
ZA988886A ZA988886B (en) 1997-10-10 1998-09-29 Formulation for treatment of osteoporosis
EP98948029A EP1021194B1 (en) 1997-10-10 1998-10-05 New improved formulation for treatment of osteoporosis
DE69814656T DE69814656T2 (de) 1997-10-10 1998-10-05 Neue verbesserte formulierung zur behandlung der osteoporose
JP2000515605A JP2001519398A (ja) 1997-10-10 1998-10-05 骨粗鬆症の治療のための新規な改良された処方物
AU94691/98A AU9469198A (en) 1997-10-10 1998-10-05 New improved formulation for treatment of osteoporosis
ES98948029T ES2200378T3 (es) 1997-10-10 1998-10-05 Nueva formulacion mejorada para el tratamiento de la osteoporosis.
EP03001707A EP1310259A3 (en) 1997-10-10 1998-10-05 Formulation comprising a biphosphonate and an absorption enhancing agent for the treatment of osteoporosis
PT98948029T PT1021194E (pt) 1997-10-10 1998-10-05 Nova formulacao melhorada para tratamento da osteoporose
ARP980104956A AR015946A1 (es) 1997-10-10 1998-10-05 Formulacion farmaceutica que comprende bifosfonatos, proceso para su preparacion, uso de la formulacion para la fabricacion de un medicamento, metodo parala inhibicion de la reabsorcion osea, y metodo para el tratamiento y prevencion de osteoporosis
DK98948029T DK1021194T3 (da) 1997-10-10 1998-10-05 Ny forbedret formulering til behandling af osteoporose
US09/171,950 US6372728B1 (en) 1997-10-10 1998-10-05 Formulation for treatment of osteoporosis
PCT/SE1998/001790 WO1999018972A1 (en) 1997-10-10 1998-10-05 New improved formulation for treatment of osteoporosis
AT98948029T ATE240107T1 (de) 1997-10-10 1998-10-05 Neue verbesserte formulierung zur behandlung der osteoporose
SI9830488T SI1021194T1 (en) 1997-10-10 1998-10-05 New improved formulation for treatment of osteoporosis
SA98190775A SA98190775A (ar) 1997-10-10 1998-11-18 صيغة جديدة مطورة لعلاج تخلخل العظام

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703691A SE9703691D0 (sv) 1997-10-10 1997-10-10 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
SE9703691D0 true SE9703691D0 (sv) 1997-10-10

Family

ID=20408561

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9703691A SE9703691D0 (sv) 1997-10-10 1997-10-10 Pharmaceutical compositions

Country Status (14)

Country Link
US (1) US6372728B1 (da)
EP (2) EP1310259A3 (da)
JP (1) JP2001519398A (da)
AR (1) AR015946A1 (da)
AT (1) ATE240107T1 (da)
AU (1) AU9469198A (da)
DE (1) DE69814656T2 (da)
DK (1) DK1021194T3 (da)
ES (1) ES2200378T3 (da)
PT (1) PT1021194E (da)
SA (1) SA98190775A (da)
SE (1) SE9703691D0 (da)
WO (1) WO1999018972A1 (da)
ZA (1) ZA988886B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038693A1 (fr) * 1998-12-25 2000-07-06 Toray Industries, Inc. Inhibiteurs de la production d'interleukine-6
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
SI1591122T1 (sl) * 2000-06-20 2013-02-28 Novartis Ag Postopek za aplikacijo bisfosfonatov
ES2394211T3 (es) * 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
JP4381805B2 (ja) 2001-07-02 2009-12-09 メリオン リサーチ スリー リミテッド 生物活性材料の送達
US7820197B2 (en) 2002-02-14 2010-10-26 Astellas Pharma Inc. Percutaneous preparations
JP4546704B2 (ja) * 2002-02-14 2010-09-15 救急薬品工業株式会社 経皮投与製剤
WO2003095029A1 (en) 2002-05-10 2003-11-20 F. Hoffmann-La Roche Ag Bisphosphonic acid for the treatment and prevention of osteoporosis
ITMI20032175A1 (it) * 2003-11-11 2005-05-12 Tiberio Bruzzese Formulazioni farmaceutiche di bisfosfonati destinate
US20050182028A1 (en) * 2004-02-13 2005-08-18 Chen Chih-Ming J. Pharmaceutical formulation for oral delivery of bisphosphates
EP2283825B1 (en) * 2004-05-24 2022-04-13 Allergan Pharmaceuticals International Limited Enteric solid oral dosage form of a bisphosphonate containing a chelating agent
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
JP5256425B2 (ja) * 2005-04-08 2013-08-07 リングアル コンセグナ ピーティーワイ エルティーディー 口腔送達システム
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
KR20080111070A (ko) * 2006-03-17 2008-12-22 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 비스포스포네이트 화합물 및 방법
US7704977B2 (en) * 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
JPWO2007132714A1 (ja) * 2006-05-16 2009-09-24 日清オイリオグループ株式会社 骨密度増加剤
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
JP2011519928A (ja) * 2008-05-07 2011-07-14 メリオン・リサーチ・Ｉｉｉ・リミテッド ペプチドの組成物及びその調製方法
CA2751854A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
CN105267145B (zh) * 2015-11-01 2019-06-21 袁旭东 双膦酸盐的自乳化配方和相关剂型

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL175882C (nl) * 1977-03-28 Procter & Gamble Farmaceutisch preparaat, dat een verbinding met ontstekingtegengaande werking bevat.
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
DE69023844T2 (de) * 1989-09-06 1996-06-20 Merck & Co Inc Acyloxymethylester der Bisphonsäuren als Knochenresorptions-Inhibitoren.
SE9003100D0 (sv) 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
JPH08507078A (ja) 1993-02-17 1996-07-30 スミスクライン・ビーチャム・コーポレイション 治療用ペプチド含有のミクロエマルジョン
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon

Also Published As

Publication number Publication date
EP1310259A3 (en) 2003-05-21
ES2200378T3 (es) 2004-03-01
WO1999018972A1 (en) 1999-04-22
DE69814656D1 (de) 2003-06-18
EP1021194A1 (en) 2000-07-26
PT1021194E (pt) 2003-09-30
AU9469198A (en) 1999-05-03
ATE240107T1 (de) 2003-05-15
EP1310259A2 (en) 2003-05-14
AR015946A1 (es) 2001-05-30
DE69814656T2 (de) 2004-03-25
JP2001519398A (ja) 2001-10-23
ZA988886B (en) 1999-04-12
EP1021194B1 (en) 2003-05-14
US6372728B1 (en) 2002-04-16
DK1021194T3 (da) 2003-09-01
SA98190775A (ar) 2005-12-03

Similar Documents

Publication Publication Date Title
SE9703691D0 (sv) Pharmaceutical compositions
SE9901272D0 (sv) New improved formulation
IL149681A0 (en) Polymorphic form of atorvstatin calcium
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
BR9809793A (pt) Monoésteres de probucol para o tratamento de doença inflamatória e cardiovascular
PL1663185T3 (pl) Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego
PT1047406E (pt) Composicoes farmaceuticas autoclavaveis contendo um agente quelante
ATE212846T1 (de) Bisphosphonat und anti-resorption agentien, enthaltende zusammensetzungen zur hemmung der knochenschwund
EE200000741A (et) Kompositsioon osteoporoosi ja menopausi sündroomist tingitud muutuste ennetamiseks ja/või raviks
DK0679393T3 (da) Pharmaceutisk præparat til behandling af osteoporose indeholdende xanthohumol
ES2193919T3 (es) Inhibidores de la enzima convertidora de endotelina.
ID28460A (id) Komposisi dan metoda untuk perlakuan dan pencegahan penyakit tulang dengan menggunakan tocotrienol
BR9305961A (pt) Compostos utilizáveis em produtos de contraste para radiografia
DK0674902T3 (da) Sammensætninger til forbedring af immunreaktionen
ATE277026T1 (de) Naphthylverbindungen, zusammensetzungen und verfahren
ATE278684T1 (de) Benzo(b)thiophen-verbindungen, zwischenprodukte, verfahren und zusammensetzungen
ATE245637T1 (de) Benzothiophenverbindungen, zubereitungen und verfahren
DE69724548D1 (de) Substituierte 2,3-Aryl-Benzothiophene und ihre östrogene Aktivität
EP1147773A4 (en) DRUG COMPOSITIONS FOR TREATING BONE LESIONS IN MULTIPLE MYELOMA
ATE244230T1 (de) Dihydrobenzofluorenverbindungen, zwischenprodukte,zusammensetzungen und methode
ATE259361T1 (de) Benzothiophenverbindungen, zwischenprodukte, zusammensetzungen und methode
PT832883E (pt) Compostos de tetrahidrobenzo(a)fluoreno e metodos de uso
DE69711528T2 (de) Naphthofluorenverbindungen, Zwischenverbindungen, Zusammensetzungen und Verfahren
TWI226833B (en) Pharmaceutical composition for inhibiting bone resorption
ATE361119T1 (de) Prävention und therapie von leberzirrhosen